UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
 and Lead Plaintiff Deadline - EconoTimes)
NEW YORK, Nov. 28, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Allergan PLC (“Allergan” or the “Company”) (NYSE:AGN) and/or Actavis plc and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Allergan between February 25, 2014 and November 3, 2016, both dates inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Both Allergan and Actavis were involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Allergan and Actavis for alleged price manipulation; (3) as a result, Allergan and Actavis lacked effective internal controls; and (4) consequently, public statements by Allergan and Actavis were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/agn or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Allergan, you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
